Our global list of drug combinations
The following is a list of products listed by our company, which is only for medical professionals to refer to.
YISAIPU （Recombinant human type II tumor necrosis factor receptor - antibody fusion protein)
YISAIPU was marketed in 2005 and is the first antibody fusion protein medicine marketed in the rheumatism field of China. 3 kinds of indications were approved by the NMPA: Treatment of rheumatoid arthritis (approved in 2005), ankylosing spondylitis and psoriasis (approved in 2007). It is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.
| Indication | Manufacturing base | Dosage form & Dosage |
|
Moderate to severe rheumatoid arthritis; Moderate to severe plaque psoriasis (PS) in adults aged 18 or above; Active ankylosing spondylitis. |
Shanghai manufacturing base | 12.5 mg/bottle; 25 mg/bottle |